Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. (Q46769274)

From Wikidata

Jump to navigation Jump to search

scientific article published in January 2013

edit

Language	Label	Description	Also known as
English	Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.	scientific article published in January 2013

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

meta-analysis

0 references

title

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

main subject

phase III clinical trial

0 references

belimumab

1 reference

based on heuristic

inferred from title

author

Cynthia Aranow

series ordinal

3

object named as

C Aranow

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

Ellen M Ginzler

series ordinal

10

object named as

E M Ginzler

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

Mary Anne Dooley

series ordinal

1

object named as

M A Dooley

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

author name string

F Houssiau

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

D P D'Cruz

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

A Askanase

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

D A Roth

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

Z J Zhong

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

S Cooper

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

W W Freimuth

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

BLISS-52 and -76 Study Groups

series ordinal

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

publication date

1 January 2013

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

published in

Lupus

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

volume

22

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

issue

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

page(s)

63-72

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

cites work

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

Predictors of survival in systemic lupus erythematosus

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

Mortality in systemic lupus erythematosus

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

Immunologic factors and clinical activity in systemic lupus erythematosus

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

Novel evidence-based systemic lupus erythematosus responder index

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1177%2F0961203312465781

retrieved

21 January 2018

Identifiers

DOI

10.1177/0961203312465781

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

PubMed publication ID

23263865

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23263865

retrieved

25 December 2017

reference URL

http://europepmc.org/abstract/MED/23263865

ResearchGate publication ID

233976934

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46769274&oldid=1619155851"